ARDS metabolic fingerprints : characterization, benchmarking, and potential mechanistic interpretation
In this study, we aimed to identify acute respiratory distress syndrome (ARDS) metabolic fingerprints in selected patient cohorts and compare the metabolic profiles of direct versus indirect ARDS and hypoinflammatory versus hyperinflammatory ARDS. We hypothesized that the biological and inflammatory processes in ARDS would manifest as unique metabolomic fingerprints that set ARDS apart from other intensive care unit (ICU) conditions and could help examine ARDS subphenotypes and clinical subgroups. Patients with ARDS (n = 108) and ICU ventilated controls (n = 27) were included. Samples were randomly divided into 2/3 training and 1/3 test sets. Samples were analyzed using 1H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry. Twelve proteins/cytokines were also measured. Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to select the most differentiating ARDS metabolites and protein/cytokines. Predictive performance of OPLS-DA models was measured in the test set. Temporal changes of metabolites were examined as patients progressed through ARDS until clinical recovery. Metabolic profiles of direct versus indirect ARDS subgroups and hypoinflammatory versus hyperinflammatory ARDS subgroups were compared. Serum metabolomics and proteins/cytokines had similar area under receiver operator curves when distinguishing ARDS from ICU controls. Pathway analysis of ARDS differentiating metabolites identified a dominant involvement of serine-glycine metabolism. In longitudinal tracking, the identified pathway metabolites generally exhibited correction by 7-14 days, coinciding with clinical improvement. ARDS subphenotypes and clinical subgroups were metabolically distinct. However, our identified metabolic fingerprints are not ARDS diagnostic biomarkers, and further research is required to ascertain generalizability. In conclusion, patients with ARDS are metabolically different from ICU controls. ARDS subphenotypes and clinical subgroups are metabolically distinct.
| Errataetall: |
CommentIn: Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1067-L1068. - PMID 34668417 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:321 |
|---|---|
| Enthalten in: |
American journal of physiology. Lung cellular and molecular physiology - 321(2021), 1 vom: 01. Juli, Seite L79-L90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Metwaly, Sayed [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2021 Date Revised 30.11.2021 published: Print-Electronic CommentIn: Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1067-L1068. - PMID 34668417 Citation Status MEDLINE |
|---|
| doi: |
10.1152/ajplung.00077.2021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325021341 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325021341 | ||
| 003 | DE-627 | ||
| 005 | 20231225191541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1152/ajplung.00077.2021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325021341 | ||
| 035 | |a (NLM)33949201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Metwaly, Sayed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ARDS metabolic fingerprints |b characterization, benchmarking, and potential mechanistic interpretation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2021 | ||
| 500 | |a Date Revised 30.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1067-L1068. - PMID 34668417 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In this study, we aimed to identify acute respiratory distress syndrome (ARDS) metabolic fingerprints in selected patient cohorts and compare the metabolic profiles of direct versus indirect ARDS and hypoinflammatory versus hyperinflammatory ARDS. We hypothesized that the biological and inflammatory processes in ARDS would manifest as unique metabolomic fingerprints that set ARDS apart from other intensive care unit (ICU) conditions and could help examine ARDS subphenotypes and clinical subgroups. Patients with ARDS (n = 108) and ICU ventilated controls (n = 27) were included. Samples were randomly divided into 2/3 training and 1/3 test sets. Samples were analyzed using 1H nuclear magnetic resonance spectroscopy and gas chromatography-mass spectrometry. Twelve proteins/cytokines were also measured. Orthogonal partial least squares discriminant analysis (OPLS-DA) was used to select the most differentiating ARDS metabolites and protein/cytokines. Predictive performance of OPLS-DA models was measured in the test set. Temporal changes of metabolites were examined as patients progressed through ARDS until clinical recovery. Metabolic profiles of direct versus indirect ARDS subgroups and hypoinflammatory versus hyperinflammatory ARDS subgroups were compared. Serum metabolomics and proteins/cytokines had similar area under receiver operator curves when distinguishing ARDS from ICU controls. Pathway analysis of ARDS differentiating metabolites identified a dominant involvement of serine-glycine metabolism. In longitudinal tracking, the identified pathway metabolites generally exhibited correction by 7-14 days, coinciding with clinical improvement. ARDS subphenotypes and clinical subgroups were metabolically distinct. However, our identified metabolic fingerprints are not ARDS diagnostic biomarkers, and further research is required to ascertain generalizability. In conclusion, patients with ARDS are metabolically different from ICU controls. ARDS subphenotypes and clinical subgroups are metabolically distinct | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ARDS heterogeneity | |
| 650 | 4 | |a ARDS metabolic fingerprints | |
| 650 | 4 | |a ARDS metabolomics | |
| 650 | 4 | |a ARDS subphenotypes | |
| 650 | 4 | |a acute respiratory distress syndrome (ARDS) | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Côté, Andréanne |e verfasserin |4 aut | |
| 700 | 1 | |a Donnelly, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Banoei, Mohammad M |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chel H |e verfasserin |4 aut | |
| 700 | 1 | |a Andonegui, Graciela |e verfasserin |4 aut | |
| 700 | 1 | |a Yipp, Bryan G |e verfasserin |4 aut | |
| 700 | 1 | |a Vogel, Hans J |e verfasserin |4 aut | |
| 700 | 1 | |a Fiehn, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Winston, Brent W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of physiology. Lung cellular and molecular physiology |d 2000 |g 321(2021), 1 vom: 01. Juli, Seite L79-L90 |w (DE-627)NLM105748501 |x 1522-1504 |7 nnns |
| 773 | 1 | 8 | |g volume:321 |g year:2021 |g number:1 |g day:01 |g month:07 |g pages:L79-L90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1152/ajplung.00077.2021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 321 |j 2021 |e 1 |b 01 |c 07 |h L79-L90 | ||